Private equity firms Apax Partners, Blackstone, Carlyle and KKR are in talks to buy a significant stake in Wockhardt's domestic formulations business, according to a report in The Economic Times.
Moneycontrol was the first to report that most private equity funds are keen on a majority stake in the domestic formulation business.
Wockhardt has told investment firm Moelis & Company that it intends to sell a 40 percent stake, the report said. But interested purchasers are eyeing a controlling interest of 51 percent.
The valuation of Wockhardt's domestic formulations business is pegged at Rs 4,000-4,500 crore.
Torrent Pharma has also expressed interest, the report said.
Habil Khorakiwala-owned Wockhardt in 2018 released nine new products in the Indian market.
The company's key domestic brands include Aceroc, Ace Proxyvon, Biovac-B, Brozedex, Clopione, Cavidin INH, Gainehair Solution, Viscodyne and Zedex.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!